Secondary analysis of a 30-week RCT in 154 people with schizophrenia, prediabetes and obesity on second-generation antipsychotics: semaglutide vs placebo lowered fasting glucose (-0.87 mmol/L) and insulin resistance; beta-cell function did not change significantly.
Secondary analysisn = 154
Ganeshalingam et al. Semaglutide Effects on Insulin Sensitivity and β-Cell Function in Patients With Schizophrenia, Prediabetes, and Obesity Treated With Second-Generation Antipsychotics: Findings From the HISTORI Trial, a 30-Week Randomized, Placebo-Controlled Trial With Semaglutide 1.0 mg Weekly